LRI Children s Hospital

Similar documents
Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Admission of a Child/Young Person with Cystic Fibrosis Clinical Guideline V3.0 May 2018

Appendix D Clinical specialist statement template

Guidelines for the use of Nebulised Colistemethate Sodium (Colomycin) Injection () in Pseudomonas aeruginosa Lung Infections in Adults

Inhaled Therapy - for further information, see LTHT Nebuliser Guidelines for Adults or Children

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.

Pseudomonas aeruginosa eradication guideline

Contents. Who should read / have access to this document? What is new in this version?

Dornase alfa (Pulmozyme ) for cystic fibrosis. Information for patients Pharmacy

Fraser Health pandemic preparedness

Shared Care Guideline

TRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008

Glossary. Acronyms used in cystic fibrosis peer review reports

Southern Trust Home IV Service. Guidelines for the administration of IV antibiotics

Nebulised mucolytic and antibiotic solutions for the treatment of Cystic Fibrosis in paediatric patients NOTES to the GP

Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines

Cystic Fibrosis Antibiotic Guidelines

Palliative and Supportive Care in Cystic Fibrosis

Inhaled Antibiotics in Non-CF. Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom

Antibiotic guideline in Adult Cystic Fibrosis

CYSTIC FIBROSIS INPATIENT PROTOCOL PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES DEFINITIONS EQUIPMENT

Cystic Fibrosis Panel Applications (Dornase Alfa) Contents

Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

(PLACE PATIENT LABEL HERE) Date: Time: Assessment nurse: Sign: STOP!

P atients with cystic fibrosis (CF) experience repeated

Intervention Study 2016 West ISD. Gillian Ritchie Clinical Pharmacist

Who should read this document 2 Key points 2 Background/ Scope 2 What is new in this version 2 Policy/Procedure/Guideline 3

PEDIATRIC CYSTIC FIBROSIS PLAN - Phase:.

Document ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy

PHYSICIAN SIGNATURE DATE TIME

Medication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016

Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.

OPAT FOR INFECTION IN BRONCHIECTASIS

BNF CHAPTER 3: RESPIRATORY

Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis

Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

Developed By Name Signature Date

Antibiotic line locks for central venous catheters in adult patients on haemodialysis

UK Cystic Fibrosis Registry

Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?

500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing

Bronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago

CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017

New Medicines Committee Briefing. July Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection

Nottingham University Hospitals Children and Young Persons Cystic Fibrosis Unit Management Guidelines

This letter authorises the extended use of the following guidance until 1st December 2018:

THE WINSTON CHURCHILL MEMORIAL TRUST OF AUSTRALIA. Report by Jamie Wood BSc. (Physiotherapy) Churchill Fellow

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department

Contributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.

PPP 1. Continuation, modification, and discontinuation of a medication

IR Central Venous Access [ ] Pre Procedure

Amy-Jo Hooley Specialist Clinical Pharmacist

Management of acute asthma in children in emergency department. Moderate asthma

A Clinical Guideline for the use of Intravenous Aminophylline in Acute Severe Asthma in Children

Cardiac Catheter Labs Intravenous Drug Therapy Guide

StRs and CT doctors in haematology. September Folinic acid dose modified.

Nebulised tobramycin for cystic fibrosis. Information for patients Pharmacy

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

LRI Children s Hospital

Joint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics

Journal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010

Drug Allergy A Guide to Diagnosis and Management

Nebulised (inhaled) Colistin (Colomycin )

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

Developed By Name Signature Date

IN USE PRODUCT SAFETY ASSESSMENT REPORT FOR COLISTIMETHATE SODIUM

PROCEDURE REFERENCE NUMBER SABP/EXECUTIVE BOARD/0017/PROCEDURE15 PROCEDURE NAME MEDICINES PROCEDURE 15: METHOTREXATE

Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines

Clinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)

Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)

Haemodialysis central venous catheter-related sepsis management guideline Version 3. NAME M. Letheren Chair Clinical Effectiveness Advisory Group

(Max 2 g) = to nearest 250 mg

Children s Hospital, LHSC Cystic Fibrosis: Paediatric Clinic

Document Details. Patient Group Direction

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Patient Profile. Patient s details Initials: IF Age: 40 Gender: Male. Weight: 139.7kg Height: 510 metres BMI: >47

Standard Operating Procedure for the Prevention and Treatment of Oral Mucositis

December 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide

Cystic Fibrosis the future

All about the adult cystic fibrosis service

ADULT (>16) ACUTE SICKLE PAIN GUIDELINE

Eradication regimens for early or recurrent Pseudomonas aeruginosa infection

New Medicine Assessment

Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages)

Hypertonic Saline (7%) Administration Guideline (adults)

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS

Cystic Fibrosis Foundation Patient Registry 2013

DR J HARTY / DR CM RITCHIE / DR M GIBBONS

Guideline scope Neonatal parenteral nutrition

Appendix: Sample prescription form. The following sample prescription form gives examples of sections found in most hospital prescription forms.

Children & Young People s Directorate Paediatric-Neonatal Guidelines Checklist & Version Control Sheet

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

Guidance for the Use of Subcutaneous Furosemide by Continuous Infusion for Heart Failure in Community Settings

Care Homes - Homely Remedies Protocol

Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT

Transcription:

Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval date: January 2019 Version: V 4 Revision due: January 2022 Written by: Sarah Popple Trust Ref: C35/2016 1. Introduction and scope This guideline should be used in conjunction with the cystic fibrosis (CF) inpatient guideline and the injectable medicines guide for children. The purpose of this guideline is to provide practical information to aid prescribing for this complex group of patients. Related Documents: Cystic Fibrosis Related Diabetes C9/2018 Management of Emergencies of Paediatric Cystic Fibrosis C64/2015 Cystic Fibrosis Outpatients Care C38/2016 Cystic Fibrosis Inpatient Chest Exacerbations C36/2016 Policy for Documentation of Medication Allergies B2/2013 Management of Suspected Anaphylaxis in Children Under 16 years C34/2015

Title: Prescribing in Cystic Fibrosis Page 2 of 10 2. Antibiotic Treatment: Cystic fibrosis patients in general need higher doses of antibiotics than other children due to increased clearance and volume of distribution. Children with CF are usually given dual therapy when treating pseudomonas aeruginosa to limit emergence of resistance, for a duration of 10-14 days. Beta lactam antibiotics and aminoglycosides are considered to be synergistic. For dosing and monitoring information of individual drugs please see the Paediatric Cystic Fibrosis Drug Formulary in the appendices or follow links below; For intravenous (IV) drugs click here http://insitetogether.xuhltr.nhs.uk/sp2007/pharmacy/cf%20iv%20drug%20formulary%20fi NAL%20NOV%202018.pdf For oral (PO) drugs click here http://insitetogether.xuhltr.nhs.uk/sp2007/pharmacy/cf%20oral%20drug%20formulary% 20FINAL%20NOV%202018.pdf For nebulised drugs click here http://insitetogether.xuhltr.nhs.uk/sp2007/pharmacy/cf%20inhaled%20drug%20formular Y%20FINAL%20Feb%202019.pdf Allergy status must always be confirmed and documented before prescribing including the nature of the reaction as per the UHL Allergy Policy (see related documents pg. 1) Choice of antibiotics will usually be previously determined by the CF multidisciplinary team. Prescribe clearly on inpatient chart including flushes / heparin lock. Sodium Chloride 0.9% 10ml after each antibiotic Heparin Saline 10units/ml 2ml for cannula or 4ml for longlines Heparin Saline 100units/ml 4ml for portacaths* * care with this strength of heparin in younger patients as three times daily exposure of heparin may approach 1/4 of an anticoagulant dose in patients <12kg. If necessary use a smaller volume or 10units/ml. Nebulised aminoglycosides should not be administered concurrently with intravenous aminoglycosides. The aminoglycosides used in CF are tobramycin and amikacin. Colistin (Colomycin / Promixin ) is also stopped on some occasions to give a break from treatment while on IV therapy but the CF team may

Title: Prescribing in Cystic Fibrosis Page 3 of 10 decide to continue it in some patients. It should not be continued if the patient is to receive intravenous colistin. Patients receiving aminoglycosides must be adequately hydrated. Consider IV fluids if vomiting or diarrhoea. Prophylactic oral antibiotics (usually BD flucloxacillin, BD co-amoxiclav or 3x weekly azithromycin) are also stopped for the duration of IV course (macrolides and ciprofloxacin in NTM patients are continued as part of the regimen) All patients with a long line or accessed portacath should receive the appropriate MRSA decolonisation regimen as an inpatient. Yellow stickers are available on the wards to facilitate prescribing. First line IV antibiotics: For younger patients who have not isolated Pseudomonas aeruginosa in the previous year, cefuroxime may be used as monotherapy unless cultures and sensitivities indicate otherwise. This broad spectrum antibiotic will cover the main pathogens found in younger cystic fibrosis patients including streptococcus, methicillin-sensitive Staphylococcus aureus and Haemophilus influenza. Patients who isolate Pseudomonas aeruginosa: Our usual combination of antibiotics for patients who have isolated Pseudomonas aeruginosa in the previous year, or who are known to be colonised, is ceftazidime IV + tobramycin IV. For patients that have also recently isolated, or have a repeated history of isolating methicillin-sensitive Staphylococcus aureus, additional oral flucloxacillin may be prescribed or ceftazidime replaced with either tazocin or meropenem. This will depend on known sensitivities, allergy status or potential for the patient to be treated at home on IVs. Please note that meropenem is not available as a pre -made antibiotic from homecare. Non-Tuberculous Mycobacterium (NTM) Patients with non-tuberculous mycobacterium (NTM) will receive an i n t e n s i v e r e g i m e n w i t h a combination of 4-5 drugs both IV and oral for a d u r at ion of 3 weeks under specialist advice. Treatment is for a duration of 3 weeks therefore be mindful of administration times to ensure patients get adequate sleep. Also aim to give drugs consecutively to limit number of times the line / port is accessed and number of heparin flushes per day. Consideration should be given to the emetogenicity of these regimens, particularly those including tigecycline or imipenem, and appropriate antiemetics prescribed.

Title: Prescribing in Cystic Fibrosis Page 4 of 10 Home IV Antibiotic Prescriptions Some patients will go home for all or part of their 2 week course of antibiotics at the discretion of the CF team. The first dose of all courses must be administered in hospital. Patients should usually stay for 48 hours to ensure full review by the multidisciplinary team. Patients either go home with vials for parents to draw up and administer or pre-made antibiotics will be provided via homecare. Homecare is co-ordinated by the CF team and paediatric pharmacy team. All patients will require a full TTO on ICE. All antibiotics and flushes should be prescribed and source selected as homecare or pharmacy. Ensure that other medications as on admission is also indicated on the TTO to avoid regular medications being removed from the patients repeat prescription. Ideally they should be prescribed in full. All patients should be issued with one adrenaline pen (Epipen or if unavailable Jext ) prescribed as in case of anaphylaxis. Patients may have been issued one recently for a prvious course of IVs. Confirm with parent / carer that they still have it and ensure they have checked the expiry.training is nurse led for new patients. Dose 15-30 kg 150 micrograms >30 kg 300 micrograms For those receiving vials ensure the following is prescribed; Antibiotic amps or vials Appropriate reconstitution solution (see IV administration guide / pharmacist) Appropriate diluent if infusion necessary (see IV administration guide / pharmacist) Flush for long line / portacath. o Heparin Sodium 100 units / ml for ports 4ml flush* o Heparin Sodium 10 units / ml for longline 2-4ml flush o Sodium Chloride 0.9% (ports and lines) 10ml flush Dispensing these items is time consuming for pharmacy. Please inform the CF pharmacist / paediatric pharmacy team as soon as possible of patients who are going home on IVs so that a supply can be made in a timely manner. *see note above regarding 100units/ml heparin in younger patients.

Title: Prescribing in Cystic Fibrosis Page 5 of 10 Nebulised Drugs For further information see nebulised drug formulary Antibiotics All first doses should be given in hospital with pre and post spirometry to assess for bronchospasm Always give nebulised antibiotics AFTER physio. Stop nebulised aminoglycosides during admission in patients receiving IV aminoglycosides (see above). Nebulised colistin (Colomycin / Promixin ) may be continued at the discretion of the CF team. Promixin is only administered via the I-neb (patient s own). Mucolytics DNase (Dornase alfa / Pulmozyme ) should be given 1 hour prior to chest physiotherapy, or last thing before bed. Usually prescribed at 12pm as an inpatient to fall between twice daily physiotherapy sessions. DNase can be administered via the I-neb. Dose is 1ml of solution. (Green chamber) Hypertonic saline (sodium chloride) 3.5-7% may be prescribed PRN to aid mucus clearance during inpatient stays Ensure salbutamol inhaler is prescribed PRN. Pre-treat hypertonic saline with 4-6puffs salbutamol as bronchospasm is common. Hypertonic saline can be administered via the I-neb as a 1ml dose nebulised twice consecutively (using lilac chamber). Vitamins, Pancreatic Enzymes, Nutritional Supplements All of the above should be prescribed on the inpatient chart Patients are usually on Vitamins A+D (Dalivit for younger pts) and Vitamin E (alpha tocopheryl) capsules (75 unit) / suspension (1mg/ml). Check dose with patient / carer. Creon 10,000, 25,000 and creon micro for younger patients are most commonly used.prescribe PRN for meals and snacks, no maximum. See oral drug formulary for further information 3. Education and Training None required

Title: Prescribing in Cystic Fibrosis Page 6 of 10 4. Monitoring and Audit Criteria Key Performance Indicator Adherence to outlined prescription requirements Method of Assessment Frequency Lead Reporting Arrangements Retrospective or prospective review of TTOs and drug charts Every 2 years Sarah Popple Senior Pharmacist Paediatrics Local clinical practice group and Quality & Safety lead 5. Supporting Documents and Key References NICE guideline ng78 Cystic Fibrosis: diagnosis and management. October 2017. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group; 3 rd edition (May 2009) online updates BNF for children 2017-2018 http:/www.medicines.org.uk Specifications of Product Characteristics accessed May15. 9. Key Words Cystic fibrosis, Antibiotics, Children, Colistin, Tobramycin, Amikacin, Mucolytics, Children, Formulary, CF. The Trust recognises the diversity of the local community it serves. Our aim therefore is to provide a safe environment free from discrimination and treat all individuals fairly with dignity and appropriately according to their needs. As part of its development, this policy and its impact on equality have been reviewed and no detriment was identified.

Title: Prescribing in Cystic Fibrosis Page 7 of 10 Guideline Lead (Name and Title) Sarah Popple Senior Pharmacist Paediatrics CONTACT AND REVIEW DETAILS Executive Lead : Chief Nurse Details of Changes made during review: Extensive changes made to antibiotic prescribing Following Added: Page 1: Related documents Page 2: Children with CF are usually given dual therapy when treating pseudomonas aeruginosa to limit emergence of resistance, for aduration of 10-14 days. Beta lactam antibiotics and aminoglycosides are considered to be synergistic. For dosing and monitoring information of individual drugs please see the Paediatric Cystic Fibrosis Drug Formulary; Heparin Saline 100units/ml 4ml for portacaths* * care with this strength of heparin in younger patients. Consider IV fluids if vomiting or diarrhoea. Page 3: All patients with a long line or accessed portacath should receive the appropriate MRSA decolonisation regimen as an inpatient. Yellow stickers are available on the wards to facilitate prescribing. Page 4: All patients will require a full TTO on ICE. All antibiotics and flushes should be prescribed and source selected as homecare or pharmacy. All first doses should be given in hospital with pre and post spirometry to assess for bronchospasm Page 5 Creon 25,000 Added Appendix: Children s Hospital Cystic Fibrosis Drug Formulary Intravenous Drugs, Oral Drugs & Inhaled Drugs

Appendices: Title: Prescribing in Cystic Fibrosis Page 8 of 10

Title: Prescribing in Cystic Fibrosis Page 9 of 10

Title: Prescribing in Cystic Fibrosis Page 10 of 10